UBS has upgraded AstraZeneca to a ‘buy’, citing the London-listed pharmaceutical firm’s "sector-leading" drug pipeline.

Morgan Stanley has initiated coverage of pharma giant AstraZeneca with an 'overweight' rating, recommending investors to ...

Highlights,Lexeo Therapeutics stock shows fluctuations in market performance, reflecting changes in financial ...

Highlights,Revised Q4 per share profit forecast now stands at a more negative figure,Stock trading within a wide 52‑week ...

China hits back with export controls, Canada and Mexico remain under threat. USPS closes then reopens "de minimis" small ...